JP2001509029A - ヒトタンパク質 - Google Patents

ヒトタンパク質

Info

Publication number
JP2001509029A
JP2001509029A JP53460398A JP53460398A JP2001509029A JP 2001509029 A JP2001509029 A JP 2001509029A JP 53460398 A JP53460398 A JP 53460398A JP 53460398 A JP53460398 A JP 53460398A JP 2001509029 A JP2001509029 A JP 2001509029A
Authority
JP
Japan
Prior art keywords
seq
sequence
polypeptide
amino acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP53460398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001509029A5 (OSRAM
Inventor
ニ，ジアン
エイ． ローゼン，クレイグ
エル． ジェンツ，ライナー
フェン，ピン
ダブリュー． クリサンセン，ジェフリー
ワイ． ス，ジェフリー
Original Assignee
ヒューマン ジノーム サイエンシーズ，インコーポレイテッド
オークランド ユニサービシーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヒューマン ジノーム サイエンシーズ，インコーポレイテッド, オークランド ユニサービシーズ リミテッド filed Critical ヒューマン ジノーム サイエンシーズ，インコーポレイテッド
Publication of JP2001509029A publication Critical patent/JP2001509029A/ja
Publication of JP2001509029A5 publication Critical patent/JP2001509029A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP53460398A 1997-01-21 1998-01-21 ヒトタンパク質 Withdrawn JP2001509029A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3420597P 1997-01-21 1997-01-21
US3420497P 1997-01-21 1997-01-21
US60/034,204 1997-01-21
US60/034,205 1997-01-21
PCT/US1998/000960 WO1998031800A2 (en) 1997-01-21 1998-01-21 Human proteins

Publications (2)

Publication Number Publication Date
JP2001509029A true JP2001509029A (ja) 2001-07-10
JP2001509029A5 JP2001509029A5 (OSRAM) 2005-09-08

Family

ID=26710688

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53460398A Withdrawn JP2001509029A (ja) 1997-01-21 1998-01-21 ヒトタンパク質
JP53460298A Withdrawn JP2001509679A (ja) 1997-01-21 1998-01-21 レセプターをコードするポリヌクレオチドとポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP53460298A Withdrawn JP2001509679A (ja) 1997-01-21 1998-01-21 レセプターをコードするポリヌクレオチドとポリペプチド

Country Status (6)

Country Link
US (8) US6653445B1 (OSRAM)
EP (2) EP1007663A2 (OSRAM)
JP (2) JP2001509029A (OSRAM)
AU (2) AU5923398A (OSRAM)
CA (2) CA2278248A1 (OSRAM)
WO (2) WO1998031799A2 (OSRAM)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
JP2001509029A (ja) * 1997-01-21 2001-07-10 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒトタンパク質
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
HUP0002095A3 (en) 1997-02-25 2002-02-28 Corixa Corp Seattle Compounds for immunotherapy of prostate cancer and methods for their use
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
WO2000078961A1 (en) * 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6146845A (en) * 1997-04-02 2000-11-14 Smithkline Beecham Corporation Polynucleotides encoding a sialoadhesin family member-2 (SAF-2)
US6485933B1 (en) 1997-05-07 2002-11-26 Incyte Genomics, Inc. B cell receptor associated proteins
EP0879880A1 (en) * 1997-05-22 1998-11-25 Smithkline Beecham Corporation ATG-1117 (AIF-3), a homolog of allograft inflammatory factor-1/RC-9
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
CA2218199A1 (en) 1997-12-09 1999-06-09 Mcgill University Short gcg expansions in the pab ii gene for oculopharyngeal muscular dystrophy and diagnostic thereof
JP2003512291A (ja) * 1998-07-06 2003-04-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ガレクチン１１
US6168920B1 (en) 1998-08-10 2001-01-02 Incyte Genomics, Inc. Extracellular adhesive proteins
US7026448B2 (en) * 1998-09-01 2006-04-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2985200A (en) * 1999-02-03 2000-08-25 Immunex Corporation Novel sialoadhesins
AU4365800A (en) * 1999-04-21 2000-11-02 Human Genome Sciences, Inc. Galectin 11
JP2003501087A (ja) * 1999-06-09 2003-01-14 ジェネンテック・インコーポレーテッド 腫瘍の治療のための組成物と方法
US20030082586A1 (en) * 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
EP1194534A4 (en) * 1999-06-29 2004-03-24 Millennium Pharm Inc NOVEL GENES ENCODING PROTEINS THAT CAN BE USED IN DIAGNOSTIC, PREVENTIVE, THERAPEUTIC OR OTHER AREAS
US6746846B1 (en) 1999-06-30 2004-06-08 Corixa Corporation Methods for diagnosing lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6914132B1 (en) 1999-06-30 2005-07-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6667154B1 (en) * 1999-06-30 2003-12-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6509448B2 (en) 1999-06-30 2003-01-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR20020026465A (ko) * 1999-06-30 2002-04-10 다케다 야쿠힌 고교 가부시키가이샤 신규 폴리펩티드 및 그의 ｄｎａ
JP2004500029A (ja) 1999-06-30 2004-01-08 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030125245A1 (en) 1999-06-30 2003-07-03 Tongtong Wang Compositions and methods for therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
IL151533A0 (en) 2000-02-29 2003-04-10 Mitsubishi Pharma Corp Novel cyclic amide derivatives
WO2001070253A1 (en) * 2000-03-23 2001-09-27 Akzo Nobel N.V. Use of mia in immunotherapy
US20020132317A1 (en) * 2000-06-15 2002-09-19 Peyman John A. Novel interferon-induced tetraspan protein and nucleic acids encoding same
WO2002010371A1 (fr) * 2000-08-01 2002-02-07 Kyowa Hakko Kogyo Co., Ltd. Peptide acitf sur le plan physiologique et utilisation de celui-ci
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CN1373218A (zh) * 2001-02-28 2002-10-09 中国医学科学院阜外心血管病医院 炎性抑制因子Fwa116
EP2374815A1 (en) * 2004-05-28 2011-10-12 IDEXX Laboratories, Inc. Canine CD20 compositions
US7495073B2 (en) * 2005-03-24 2009-02-24 Asia Hepato Gene Company Short isoform of Annexin A10 at chromosome 4q, termed Annexin 10s (ANXA10s) and methods of use
CA2683463A1 (en) * 2007-04-11 2008-10-23 Gene Signal International Sa Anti-tumor variants and fragments of protein 497c, and uses thereof
ATE484520T1 (de) * 2007-04-11 2010-10-15 Gene Signal Int Sa Antitumorheilmittel, medikament, zusammensetzung und verwendung davon
US8372810B2 (en) * 2007-04-11 2013-02-12 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
TWI387750B (zh) * 2009-02-10 2013-03-01 Nat Defense Medical Ct Biomarker and detection method for detecting kidney disease
WO2011057188A1 (en) * 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies
EP2621526B1 (en) 2010-09-29 2018-06-06 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
US20150301068A1 (en) * 2012-01-30 2015-10-22 Vib Vzw Means and method for diagnosis and treatment of alzheimer's disease
US12257340B2 (en) 2018-12-03 2025-03-25 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3789413T2 (de) * 1986-10-03 1994-07-28 Ciba Geigy Ag Lymphokin-ähnliche Peptide.
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
FR2636953B1 (fr) 1988-09-26 1990-12-14 Roussy Inst Gustave Nouveaux polypeptides produits par des lymphocytes humains, genes codant pour ces polypeptides et applications pharmaceutiques et biologiques
US5580753A (en) 1989-05-23 1996-12-03 Ludwig Institute For Cancer Research DNA encoding the human cytokine, interleukin-9
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
DE69133159D1 (de) 1990-09-05 2003-01-02 Heart Res Inst Ltd Chemotaktische faktoren
US5536637A (en) 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
EP0710248B1 (de) 1993-07-20 1999-09-29 Roche Diagnostics GmbH Melanom-inhibierendes protein
US5527884A (en) 1993-12-21 1996-06-18 President And Fellows Of Harvard College Mediators of chronic allograft rejection and DNA molecules encoding them
DK0871702T3 (da) 1994-12-06 2005-09-19 Immunex Corp Cytokin betegnet Lerk-7
US6020169A (en) * 1995-07-20 2000-02-01 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
JP2001509029A (ja) * 1997-01-21 2001-07-10 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒトタンパク質
US6020478A (en) * 1997-02-28 2000-02-01 Incyte Pharmaceuticals, Inc. Human tumor-associated antigen
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
US6168920B1 (en) * 1998-08-10 2001-01-02 Incyte Genomics, Inc. Extracellular adhesive proteins

Also Published As

Publication number Publication date
EP1007663A2 (en) 2000-06-14
WO1998031800A2 (en) 1998-07-23
US6653445B1 (en) 2003-11-25
WO1998031799A2 (en) 1998-07-23
AU6030398A (en) 1998-08-07
CA2278248A1 (en) 1998-07-23
US7098316B2 (en) 2006-08-29
AU5923398A (en) 1998-08-07
US20080058247A1 (en) 2008-03-06
JP2001509679A (ja) 2001-07-24
US20030129696A1 (en) 2003-07-10
WO1998031800A3 (en) 1998-11-26
US20090208969A1 (en) 2009-08-20
US20050176044A1 (en) 2005-08-11
US20050119457A1 (en) 2005-06-02
US20070004008A1 (en) 2007-01-04
EP0972022A2 (en) 2000-01-19
CA2278118A1 (en) 1998-07-23
WO1998031799A3 (en) 1998-11-05
US20110151473A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
US7098316B2 (en) Human proteins
JP3675828B2 (ja) インターロイキン−１β転換酵素様アポトーシスプロテアーゼ−３および４
JP2001524814A (ja) ２８種類のヒト分泌タンパク質
JP2002502589A (ja) ４５個のヒト分泌タンパク質
JP2002523035A (ja) ４９個のヒト分泌タンパク質
JP2002533058A (ja) ９７個のヒト分泌タンパク質
JP2001017191A (ja) 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
CA2181431A1 (en) Haemopoietic maturation factor
US7084253B2 (en) Protease-activated receptor PAR4 (ZCHEMR2)
JP2002501738A (ja) ６７個のヒト分泌タンパク質
JP2002500035A (ja) ３６個のヒト分泌タンパク質
JP2003524413A (ja) プラスミノーゲン様ポリヌクレオチド、ポリペプチド、および抗体
JP2002506625A (ja) サイトカインレセプター共通γ鎖様
JP2001514024A (ja) ５０個のヒト分泌タンパク質
JP2001514885A (ja) ７０個のヒト分泌タンパク質
JP2003503010A (ja) アポトーシス関連遺伝子
JP3687974B2 (ja) スタンニウスの小体の蛋白、スタンニオカルシン
JP2003525566A (ja) １２５個のヒト分泌タンパク質
JP2003507036A (ja) レチノイドレセプター相互作用ポリヌクレオチド、ポリペプチド、および抗体
JP2002505871A (ja) ３１個のヒト分泌タンパク質
JP2001519179A (ja) ５３個のヒト分泌タンパク質
JP2004500810A (ja) Ｉｌ−６様ポリヌクレオチド、ポリペプチド、および抗体
JP2003521216A (ja) ９０個のヒト分泌タンパク質
JP2002537810A (ja) ヒトセルピンタンパク質
JP2002532054A (ja) ２９個のヒト分泌タンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050119

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060308